Highlights
- Gallium-68 enables PET imaging to locate kidney tumors expressing carbonic anhydrase IX, while lutetium-177 delivers targeted beta radiation to the same sites.
- Two patients with metastatic clear cell renal cell carcinoma received the experimental agent; one developed grade 3 radiation-induced gastritis, flagging a key safety concern.
- Tumor PET uptake reached an extraordinary SUVmax of 330, but the trial remains proof-of-concept with no confirmed clinical efficacy data yet.
- Nuclear medicine creates a high-value downstream market where isotope purity, reactor capacity, and elemental feedstocks matter more than raw mine output.
- Lutetium and gallium are emerging as enabling critical minerals across biotechnology, diagnostics, and precision medicine—a market dimension investors often overlook.
0 Comments
No replies yet
Loading new replies...
Moderator
Join the full discussion at the Rare Earth Exchanges Forum →